|Bid||50.81 x 1000|
|Ask||52.00 x 100|
|Day's Range||50.47 - 50.99|
|52 Week Range||37.38 - 51.13|
|PE Ratio (TTM)||52.86|
|Dividend & Yield||1.06 (2.08%)|
|1y Target Est||N/A|
When it completes its $5.3 billion acquisition of Waltham-based Alere later this year, Abbott Laboratories will be getting one of the world’s largest makers of point-of-care diagnostic tests, a fast-growing sector. Thanks to antitrust rules, though, Abbott (ABT) will be taking on a slimmed-down version of Alere (ALR) by the end of September. Back in January, Illinois-based Abbott agreed to divest three Alere business units that make competing products in order to secure the approval of European Union antitrust regulators.
Abiomed is primarily focused on the growth opportunity in the protected PCI area, a procedure that is applicable for patients with coronary artery disease.
To improve clinical outcomes and increase the number of patients treated in the United States using Impella, Abiomed has launched the Abiomed Impella Quality Program.